Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Beyond eNOS: Genetic influence in NO pathway affecting drug response

Full text
Author(s):
Aline Esposito [1] ; Cezar Kayzuka Cotta Filho [2] ; Riccardo Lacchini [3]
Total Authors: 3
Affiliation:
[1] Universidade de São Paulo. Departamento de Farmacologia - Brasil
[2] Universidade de São Paulo. Departamento de Farmacologia - Brasil
[3] Universidade de São Paulo. Departamento de Enfermagem Psiquiátrica e Ciências Humanas - Brasil
Total Affiliations: 3
Document type: Journal article
Source: GENETICS AND MOLECULAR BIOLOGY; v. 45, n. 3 2022-10-14.
Abstract

Abstract Nitric Oxide (NO) has important biological functions, and its production may be influenced by genetic polymorphisms. Since NO mediates the drug response, the same genetic polymorphism that alter NO levels may also impact drug therapy. The vast majority of studies in the literature that assess the genetic influence on NO-related drug response focus on NOS3 (which encodes endothelial nitric oxide synthase), however several other proteins are interconnected in the same pathway and may also impact NO availability and drug response. The aim of this study was to review the literature regarding genetic polymorphisms that influence NO in response to pharmacological agents located in genes other than NOS3. Articles were obtained from Pubmed and consisted of 17 manuscripts that assessed polymorphisms of the following targets: Arginases 1 and 2 (ARG1 and ARG2), dimethylarginine dimethylaminohydrolases 1 and 2 (DDAH1 and DDAH2), and vascular endothelial growth factor (VEGF). Here we analyze the main results of these articles, which show promising evidences that may suggest that the NO-driven pharmacological response is affected by more than the eNOS gene. The search for genetic markers may result in better understanding of the variability of drug response and turn pharmacotherapy involving NO safer and more effective. (AU)

FAPESP's process: 20/11740-9 - Evaluation of epigenetic mechanisms in response to drug treatments in genes related to Hypertension in an experimental animal model
Grantee:Cezar Kayzuka Cotta Filho
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)